End of coverage

From 5th February, we will no longer include in our research universe:Adaptimmune, ALK, argenx, Autolus, Cellectis, Galapagos, Hansa Biopharma, Heidelberg Pharma, Immatics, Immunocore, Ipsen, Moonlake Immunotherapeutics, Pharvaris, UCB, Vivoryon Therapeutics, Zealand Pharma, Nicox, GenSight Biologi

IMA203 phase 1b update to cement leadership position in PRAME

Immatics is expected to report an update in Q4 2023 from its ongoing phase 1b dose expansion trial with the autologous TCR T PRAME therapy IMA203. With this note, we recap the data so far and put forward our readout scenarios. Based on the previous interim update in May 2023, in our base case we ex

Coverage update

Given team and strategy changes, Alex Cogut is now assuming coverage of Achilles Therapeutics, Adaptimmune Therapeutics, Autolus, Calliditas, Cellectis, Galapagos, GenSight, Hansa Biopharma, Heidelberg Pharma, Immunocore, Innate Pharma, Sesorion and ValerioWe drop coverage of Celyad Oncology BioNte

Transfer of coverage

from 1st June the cover of the following companies will be transferred to Ingrid GafanhaoADAPTIMMUNE THERAPEUTICSBIONTECHHEIDELBERG PHARMAIMMATICSIMMUNOCORE HOLDINGSINNATE PHARMAONXEOOSE IMMUNOTRANSGENE

Bryan, Garnier & Co Healthcare Daily | Immatics, ISCT KOL dinner

IMA203 shows early evidence of response durability

Immatics announced interim results from the phase 1b study of IMA203, PRAME-targeting TCR T therapy, in heavily pretreated PRAME+/HLA-A*02+ solid tumours. With additional patients treated at higher dose levels (DL4 and DL5), 67% cORR looks encouraging (n=9), although expectedly slipping a bit from

TCR therapeutics coming of age

With the opportunity to tap into the intracellular target universe and efficient TCR signalling, TCR-based therapies could reach beyond other immunotherapeutics. TCR-based therapeutics showed durable clinical responses in hard-to-treat solid tumours, a significant achievement and a sign of maturity

The most comprehensive approach to TCR therapeutics

Immatics is leveraging two TCR discovery engines, XPRESIDENT and XCEPTOR, for a 360º approach to the development of TCR-based therapeutics. The company developed two technology platforms: i) ACTengine for TCR T cell therapies, and ii) TCER for TCR bispecifics. Moreover, early-stage allogeneic techn